Moderna Co-Founder Robert Langer Reclaims Billionaire Status

Moderna co-founder Robert Langer has re-entered the billionaires club, with his net worth now estimated at approximately $1.7 billion. This significant wealth surge is attributed to promising Phase 3 trial results for a messenger RNA (mRNA) cancer vaccine developed by Moderna in partnership with pharmaceutical company Merck. The announcement on Wednesday indicated that the vaccine met its goals in targeting melanoma, a type of skin cancer. Following this news, Moderna's stock price experienced a substantial increase, soaring by more than 100%. This rally propelled the value of Langer's approximately 3% equity stake in the biotech firm beyond the billion-dollar threshold. On Tuesday, his stake was valued at roughly $730 million, highlighting the dramatic impact of the trial results on his personal fortune.

This marks the second time Robert Langer has achieved billionaire status. His initial entry into the 10-figure wealth bracket occurred in November 2020, coinciding with a surge in Moderna's share price after the company announced positive Phase 3 results for its COVID-19 vaccine. During the peak of the pandemic-driven Moderna boom, Forbes reported his net worth as high as $4.9 billion in 2021. However, his wealth subsequently declined, leading to his removal from the billionaires club.

Langer, often referred to as the "Edison of Medicine," is 77 years old. His stake in Moderna was valued at approximately $343 million in early January, when the company's shares were trading at a low of $29.81. The recent resurgence in stock value has restored his position among the ultra-wealthy. Despite his financial success, Langer continues to advocate for prioritizing meaningful work and personal happiness over solely pursuing financial gain or job security. In a 2018 interview with Big Think, he advised students to choose careers that bring them happiness, rather than those offering the highest income or security.

Langer's entrepreneurial journey involved significant personal sacrifice; he reportedly turned down 20 high-paying job offers to pursue his vision of making a greater impact on the world. His dedication to innovation and his belief in the power of mRNA technology have been central to Moderna's development and success. The company, founded in 2010, has focused on leveraging mRNA to create a new class of transformative medicines. The recent success of the cancer vaccine trial underscores the potential of this platform beyond infectious diseases, offering hope for new treatments in oncology. Fortune has reached out to Moderna for comment regarding Langer's current financial standing and the company's future outlook.